C hikungunya virus (CHIKV) is a ribonucleic acid (RNA) virus, a member of the Togaviridae, that was first isolated in humans in 1952-53 in Tanzania. It is transmitted though the bites of infected female mosquitoes (Aedes species), which are aggressive daytime and nighttime biters. They also transmit the Dengue and Zika viruses.
1,2 When these viruses co-circulate in the same geographic area, it can be challenging to differentiate between the three pathogens purely on the basis of their clinical manifestations (Table 1) . Moreover co-infections are possible. 3, 4 The A. aegypti mosquito was the historical vector for CHIKV, but the virus has evolved genetically and become compatible with A. albopictus. As a result, after decades of infrequent and sporadic outbreaks, CHIKV has caused major endemic outbreaks in Africa, Asia, the Indian Ocean, and more recently the Caribbean and the Americas. 2 A. albopictus has a wider distribution than A. aegypti, which is found in tropical and subtropical regions. Native to the tropical and subtropical areas of Southeast Asia, this species has, in the past few decades, spread to many places such as the temperate zones of Europe 5, 6 and the southern and eastern United States. 7, 8 As of late July 2016, more than 3 million cases and 300 deaths had been reported in the Americas. One hundred seventy-five CHIKV cases onset were declared to ArboNET from 37 U.S. states in 2016 7 (https://www.cdc.gov- Figure 1 ). Thirteen cases from nine U.S. states had been reported for 2017 as of July 11.
The burden of acute CHIKV infection and the longlasting effect on quality of life have made this vector-borne disease a public health concern. Moreover, its high prevalence in older adults, 8, 9 who are vulnerable to severe, atypical, chronic arthritis 10, 11 and have higher hospitalization rates and mortality, 2 will soon present U.S. geriatricians with new clinical, functional, and therapeutic challenges.
SYMPTOMS
After an incubation period of 2 to 7 days, common clinical symptoms of CHIKV include abrupt onset of fever (85-100%) and polyarthralgia (87-99%). Joint pain is the most-characteristic symptom, most commonly presenting with bilateral and symmetrical manifestations affecting mainly the wrists, ankles, and phalanges and sometimes the shoulders, elbows, and knees. This can mimic rheumatoid arthritis and be severe and debilitating. Synovitis or periarticular swelling is reported in 32% to 95% of individuals, with large joint effusion occurring in 15%. Severe back pain has also been reported, as well as a wide diversity of symptoms in different physiological systems: 11, 12 headache (40-81%), neurological manifestations (16%), myalgia without myositis (arms, thighs, calves-46-59%), and macular or maculopapular rash (35%). The latter typically involves the extremities, trunk, or face. Generalized pruritus was also reported in 25% of cases, and a variety of skin and mucous membrane lesions have been reported during the acute stage, together with exacerbation of preexisting dermatoses (e.g., psoriasis) and mucosal ulcerations. Digestive symptoms such as diarrhea, vomiting, nausea, and abdominal pain also occur in 15% to 47%. Greater severity and susceptibility to debilitating chronic disease has been reported in individuals aged 65 and older. 2, 13 CURRENT CASE DEFINITION
Clinical Case Definition
An expert panel from the World Health Organization proposed a clinical case definition for the Americas in 2015 that included four categories of presentation (Table 2) (acute clinical case, atypical acute case, severe acute case, and suspected or confirmed chronic case), 12 but these clinical criteria fail to appreciate differences in older adults in whom the most-frequent clinical presentation at the acute stage differs from that most commonly observed in younger individuals. 2 A recent cross-sectional study from retrospective laboratory-confirmed cases revealed that only 8% of 267 individuals aged 65 and older had a typical clinical form. 10 Moreover, 40% of these cases could not be classified in any of the four categories listed above. Age-related changes in the immune system and the coexistence of multiple comorbid conditions 10 are some of the major factors that may contribute to the higher incidence of atypical and severe cases in these older adults.
1,2,10
Biological Case Definition CHIKV is generally diagnosed by testing serum or plasma to detect viral nucleic acids, virus-specific antibodies (immunoglobulin (Ig)M and IgG), viral particles (https:// www.cdc.gov)). Once infected, people rapidly mount a robust antibody response. IgM concentration is detectable after a few days, and neutralizing IgG is measurable within 2 weeks.
14 This antibody profile is considered for biological diagnosis. Thus, CHIKV serologic testing using enzyme-linked immunosorbent assay or indirect fluorescent antibody can be performed 8 days or more after the onset of symptoms. It is generally required that anti-CHIKV neutralizing IgG levels be 4 times as high in acute-phase specimens as in convalescent-phase specimens for diagnosis. At any time, detection of specific IgM or IgG neutralizing antibodies confirms CHIKV infection. 2 This is important for example in individuals with a history of epidemiological exposure who present with persistent or chronic symptoms. For individuals presenting 1 to 7 days after onset of symptoms, it is recommended that CHIKV viral RNA be examined by using real-time reverse-transption polymerase chain reaction. 15 A positive result confirms the diagnosis; negative results should prompt CHIKV serologic testing. Viral culture is highly sensitive at the early stage but dramatically less so 5 days after the onset of symptoms. The viral culture allows the identification of the strain, but this method should be restricted to epidemiology and research. 16 
Reasons for Spread of CHIKV to Continental United States
CHIKV was until recently considered to be a tropical disease but is now permanently established in many temperate zones, including in the Americas. It was first reported in Saint Martin Island in 2013 and in the Virgin Islands in 2014. Since then, CHIKV has spread to 45 countries and territories in South, Central, and North America. 7, 8 The first case of local transmission in the continental United States was reported in Florida in July 2014. 17 CHIKV disease became a nationally notifiable condition in the United States in 2015. State and local health departments report cases to the Centers for Disease Control and Prevention using standard case definitions (Table 2) . 12 Thus, CHIKV has travelled from its historic homes in Africa, Asia, and Southeast Asia to the temperate regions of southern Europe 5, 6 and the Caribbean 18, 19 and from there to the Americas. 7, 8 The rapid spread of the virus is in part attributable to a lack of population immunity, the broad distribution of vectors capable of transmitting CHIKV (A. albopictus), and the movement of infected individuals between regions where the infection was prevalent. 8 In addition, dissemination can occur through the travel of mosquito larvae and eggs on ships and air planes to new zones with suitable environmental and climate conditions. 3, 7 In the United States, there were 115 laboratory-confirmed cases between 2010 and 2013. The travel history of 55 cases was researched, and of these, 96% had visited Asia and 2% Africa. 8 Genetic characterization has confirmed that the strain circulating in the Caribbean and the Americas was the Asian strain. 2 Although it is tempting to speculate that climate change may have primarily contributed to the westward and northward expansion of CHIKV, human ecological and environmental factors have had a greater effect. 3 Thus, the adaptation of CHIKV infectivity to A. albopictus is probably the critical factor that has allowed the virus to spread to areas where there was minimal population immunity. 11 All cases reported in the continental United States have occurred in travelers returning from affected areas. Although no locally transmitted cases have been reported, the active viremia during the early stage of CHIKV infection eases and enables transmission through urban cycles of infection (human-vectorhuman). 2, 11 In 2017, CHIKV continues to spread actively across the Americas, and the U.S. population is immunologically na€ ıve to CHIKV and so is highly vulnerable. 2 Although the continuing geographical spread through travel and trade should remain of concern in the United States, it is unclear whether CHIKV will establish an enzootic cycle or not.
Why CHIKV Is a Threat to Older U.S. Adults
The Population Reference Bureau has recently reported that the number of U.S. citizens aged 65 and older is projected to more than double from 46 million in 2016 to more than 98 million by 2060. 20 This age group's share of the total population will rise to nearly 24% from 15% in 2016. This population is much more active than previous generations were, and this trend will probably continue. This active lifestyle, which is reflected by the amount of international travel this population undertakes, coupled with the degree of "immune insufficiency" recognized within this population, has led to a change in the profile of infectious diseases affecting these individuals. 21 This population is not only at greater risk of coming into contact with common but also with emerging pathogens (e.g., In children aged <3, joint pain is expressed as inconsolable crying, irritability, rejection of mobilization or walking. In addition to the onset of delirium, this could be observed in older adults with cognitive disorders. The diagnosis is established by detection of chikungunya viral ribonucleic acid using real-time reverse-transcription polymerase chain reaction for individuals presenting 1 to 7 days following onset of symptoms or chikungunya virus serology using enzyme-linked immunosorbent assay or indirect fluorescent antibody for individuals presenting 8 days or more after onset of symptoms. 
Susceptibility of Older Adults to CHIKV Infection
Both adaptive and innate arms of the immune system play a role in the body defense against CHIKV. 2 The B-cellmediated immunity is an important component that enables clearance of the virus at the acute stage. IgM, which appears as early as the fourth day after the onset of symptoms, significantly controls and reduces the viremia. After 10 days or so, the neutralizing capacity is attributable almost entirely to IgG. 22, 23 IgG also provides strong, long-lasting immune protection. 24, 25 Findings from studies in mice suggest that an effective cellular adaptive immunity (e.g., CD4 + T-helper cell) is also important in the control of CHIKV infection, but it also contributes to chronic musculoskeletal tissue pathology. 23 The innate immune response, during the acute stage, has also been studied, and findings suggest that CHIKV directly infects dendritic cells, macrophages, and natural killer cells. CHIKV also invades nonimmune cells (synovial fibroblasts, endothelial cell, myocytes, osteoblasts), directly contributing to some clinical symptoms, although it is unclear why some individuals present with persistent arthritis and which immune pathway controls or triggers chronic symptoms. 2 In nonhuman primates, it has also been reported that the ageassociated immune remodeling negatively limits the immune response quantitatively and qualitatively, 13, 26 which in turn contributes to atypical presentation, severe cases, and more-frequent, persistent arthropathy. 11 The question of how great an effect the age-associated immune remodeling has on the immune memory response to CHIKV in terms of magnitude (frequency of antigen-specific cells), quality (phenotype and effector function of immune cells), breadth (number of epitopes recognized), and avidity (ability of receptors to bind antigen) remains to be answered.
Compounding Effects of Comorbid Chronic Conditions
Although increases in comorbidities and advancing age are often closely linked, 27 they play independent roles in the vulnerability of older citizens to CHIKV. First, comorbid and chronic health conditions could be easily exacerbated during the acute stage of CHIKV infection. They then accentuate the negative functional effect of the virus and its associated morbidity. Comorbidities such as underlying respiratory disease, hypertension, or chronic cardiac disorders have been associated with need for hospitalization and greater disease severity. 1 Second, although an individual's age is a major contributing indicator of disease severity, there is no single cause for the age-associated immune remodeling. In addition to the normal compendium of ageassociated immunological events (e.g., thymic involution, continuous reshaping of the immune repertoire, changes in antigen-presenting cells, reduced production of na€ ıve B and T-cells), comorbid conditions contribute to the chronic low grade inflammation that further affects the quality of the immune response. 21 Finally, multiple comorbid conditions are intrinsically associated with polypharmacy, and inappropriately prescribed medications also contribute to the morbidity and mortality associated with CHIKV infections. 28 The intake of medications such as immunosuppressive drugs and nonsteroidal antiinflammatory drugs (NSAIDs) particularly has, for example, a deleterious effect in the context of this acute viral infection. 2, 11 NSAIDs have been associated with hospitalization, disease severity, and mortality. 1 Delayed or mistaken diagnosis may also contribute to greater polypharmacy. For example, the prominent rheumatic manifestations of CHIKV may lead to incorrect diagnosis and inappropriate prescription of NSAIDs.
29,30
The Burden of CHIKV Infection in Older U.S. Adults May Be Underestimated
In terms of disease burden, the symptoms of the acute phase partly explain the disease burden because CHIKV can also act as a triger for functional decline, leading to disability in some individuals and poor quality of life, particularly in older people. 9, 31 In addition to the acute responses (fever in 1-8 days, rash in 3-5 days) and symptoms, affected individuals may experience rheumatological symptoms for months and even years (5-60%). 9 Moreover, severe responses such as meningoencephalitis, multiorgan failure, hepatitis, and myocarditis or atypical presentation mainly occur in older adults, especially those with chronic medical conditions, resulting in higher mortality. 1, 32 Incapacity or limitations in normal activity occur in more than 60% of cases and significant or very significant tiredness in 47%. 11 Psychological effects have also been observed, with some individuals being depressed or demoralized. 9 The exacerbation of underlying chronic comorbid conditions by CHKV has been studied in individuals with diabetes mellitus. The infection may worthen the glycemic control and results in greater morbidity than in individuals without diabetes mellitus. 33 Working from the electronic medical recard of the Veterans Health Administration System, one study reported that overall mortality at the acute stage was low. However, and similarly to what was described for seasonal influenza infection, 35 the mortality related to CHIKV is also probably delayed to months after the acute phase. 34 In addition to recording the morbidity and mortality due to the viral infection (acute stage and persistent arthropathy) other geriatric health outcomes such as exacerbation of chronic comorbid conditions and the associated morbidity and mortality in terms of lost of independency, disability, and nursing home admission over the years after onset of symptoms also need to be considered.
Therapeutic Options in Absence of Vaccine and Antiviral Therapy

General Overview of Therapeutic Approach to CHIKV Infection
Although promising antivirals, 35, 36 immunotherapy, 37, 38 and vaccines 39, 40 are being developed, there is no effective prevention or curative treatment for CHIKV. 41 Current therapeutic recommendations commonly consist of supportive care, 2 with plenty of rest, ensuring adequate fluid intake, and use of acetaminophen or NSAIDs to reduce pain and fever at the acute stage. Aspirin and other NSAIDs must not be used until the individual has been afebrile for longer than 48 hours or until dengue is excluded, to reduce the risk of bleeding. During the acute stage, systemic glucocorticoids and other immunosuppressive medications should generally be avoided. 42 In individuals with persistent manifestation and more particularly joint symptoms persisting into the postacute phase (defined as 1-3 months after onset of infection) treatment consists of symptomatic control through the continued use of analgesia (e.g., acetaminophen) and NSAIDs. Additional analgesic benefit can be also provided with medications for neuropathic pain (e.g., pregabalin, gabapentin) and physical therapy. For more-longstanding disease (>3 months) and particularly for suspected inflammatory arthritis, individuals should be referred to a rheumatologist for further assistance and to determine whether treatment with disease-modifying antirheumatic drug therapy (methotrexate or tumor necrosis factor inhibitors) is appropriate. 43 
Management Strategies to Consider with Caution
Although the recommendations for therapeutic management of acute and postacute CHIKV infection focus on common analgesic treatments (acetaminophen, NSAIDs, opioid agonists, calcium channel a2-d ligands (pregabalin, gabapentin)), 2, 42 their application may be contraindicated. 44 Strong consideration must be given to their potential adverse effects in old, frail, comorbid, and often already polymedicated individuals. In all cases, a thorough medical history must precede management of acute or chronic pain from CHIKV infection, and a complete medication list must be obtained and reviewed to identify potential drug-drug, drug-disease interactions before initiating any therapy. 45 NSAIDs are recommended as one of the first-line options for the management of acute and chronic pain, although they should be considered for only a few select older adults and only after a trial of acetaminophen. 46 To lower the risk of NSAID-associated adverse effects, some intrinsic pharmacological properties (selectivity or nonselectivity, cyclooxygenase (COX)-1 or COX-2 affinity, half-life) should be considered. Thus, with higher affinity for COX-1 inhibition (nonselective NSAIDs) greater risk of gastrointestinal and renal side effects is seen. Of the nonselective NSAIDs, those with the lowest COX-2 affinity have the least risk of cardiovascular events (e.g., naproxen). Inversely, selective NSAIDs (lower COX-1 affinity) have the highest cardiovascular risks. 46, 47 Selective and nonselective NSAIDs should be prescribed at the lowest-possible dose, frequency, and duration. They must be monitored with caution or completely avoided in individuals with moderate to severe renal insufficiency and in those with unexplained anemia, liver insufficiency, and bleeding disorders. 46 Acetaminophen is commonly recommended as first-line therapy because of its low risk of side effects and drug-drug and drug-disease interactions. Opioids and derivatives, tramadol, and calcium channel a2-d ligands can also be considered in this population but adhering to the adage "start low and go slow." 44 
Prevention
There is no licensed vaccine for preventing CHIKV transmission, 39, 40, 48, 49 so approaches consisting of minimizing exposure to mosquitoes must be considered. Aedes mosquitoes bite primarily during daytime but also at night. They are also known as "container-breeding mosquitoes" because Aedes likes to lay eggs in and around standing water, so measures to avoid mosquito bites must include personal protection and environmental control. 3, 4 Individuals infected with CHIKV can contribute to a reduction in the spread of the infection by taking precautions to avoid being bitten by mosquitoes during the stage of active viremia. 11 To that end, the Centers for Disease Control and Prevention has edited fact sheets to explain how people can protect themselves against mosquito bites (https:// www.cdc.goc/chikungunya/fact/index.html). 50 
CONCLUSION
This review demonstrates that CHIKV infection, an emerging infectious threat with some unique features in elderly adults, should be of interest to geriatricians, including in the United States. A number of factors place older U.S. adults at risk of severe, debilitating illness from CHIKV. Given lack of antivirals and vaccines for treatment or prevention, current management of infection consists of supportive care. In spite of recommendations focusing on common analgesic treatments, caution is needed when prescribing these in old, frail, comorbid and often already polymedicated individuals. Age-associated immune remodeling and immunosenescence may contribute to the atypical course and burden of CHIKV infection seen in elderly adults and must be incorporated into future research efforts, ultimately leading to the design of innovative, targeted therapies against CHIKV transmission and disease.
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